Summary
Thermo Fisher Scientific Inc. reported robust financial performance for the first quarter ended April 3, 2010, showcasing significant year-over-year revenue growth of 19% to $2.68 billion. This increase was driven by strong demand across both the Analytical Technologies and Laboratory Products and Services segments, bolstered by strategic acquisitions and a rebound from a weaker prior-year period. The company's operating income surged by 54% to $293 million, reflecting improved profitability due to higher sales, price increases, and productivity enhancements, despite increased restructuring and other costs. The company also demonstrated a strong commitment to growth through strategic acquisitions, notably Ahura Scientific and Finnzymes, which expanded its product portfolios and market reach.
Financial Highlights
51 data points| Revenue | $2.63B |
| Cost of Revenue | $1.35B |
| Gross Profit | $1.07B |
| SG&A Expenses | $698.30M |
| Operating Expenses | $2.34B |
| Operating Income | $284.60M |
| Interest Expense | $22.30M |
| Net Income | $232.30M |
| EPS (Basic) | $0.57 |
| EPS (Diluted) | $0.56 |
| Shares Outstanding (Basic) | 409.60M |
| Shares Outstanding (Diluted) | 418.20M |
Key Highlights
- 1Total revenues increased by 19% year-over-year to $2.68 billion, driven by strong performance in both the Analytical Technologies (18% growth) and Laboratory Products and Services (19% growth) segments.
- 2Operating income saw a significant jump of 54% to $293 million, with operating margin improving to 11.0% from 8.4% in the prior year's quarter.
- 3The company completed two key acquisitions in the first quarter of 2010: Ahura Scientific for $147 million and Finnzymes for $59 million, aimed at expanding its analytical devices and molecular biology offerings, respectively.
- 4Net income rose to $232.3 million from $148.9 million in the comparable prior-year period, with diluted earnings per share increasing to $0.56 from $0.35.
- 5Cash flow from operations remained strong at $343 million, though slightly down from $359 million in the prior year, primarily due to increased investment in working capital to support sales growth.
- 6Thermo Fisher Scientific issued $750 million in senior notes in late April 2010 and announced plans to use the proceeds to redeem outstanding convertible debentures and senior subordinated notes, demonstrating proactive debt management.
- 7The company continues to invest in growth, with capital expenditures of $51 million in the quarter and identified future restructuring actions expected to yield annual cost savings of approximately $109 million.